Comparative Pharmacology
Head-to-head clinical analysis: CARDIOQUIN versus CARNEXIV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIOQUIN versus CARNEXIV.
CARDIOQUIN vs CARNEXIV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class IA antiarrhythmic agent; blocks sodium channels, slows phase 0 depolarization, prolongs action potential duration, and increases effective refractory period. Also exhibits anticholinergic and negative inotropic effects.
CARNEXIV is a formulation of carbidopa and levodopa; levodopa is converted to dopamine in the brain, replenishing depleted dopamine in the striatum, while carbidopa inhibits peripheral decarboxylation of levodopa, increasing central availability.
Quinidine gluconate extended-release: 324-648 mg orally every 8-12 hours. Quinidine sulfate immediate-release: 200-400 mg orally every 6 hours. Quinidine sulfate extended-release: 300-600 mg orally every 8-12 hours. Maximum dose: 3-4 g/day.
1 mg intravenously once daily for 7 days, followed by 1 mg orally once daily for 7 days.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours in patients with normal renal function. Prolonged in renal impairment (up to 16-40 hours) and heart failure, requiring dose adjustment.
Terminal elimination half-life is 8-12 hours in patients with normal renal function; prolonged in renal impairment (up to 24-36 hours with CrCl <30 mL/min)
Renal: 60-80% as unchanged drug and metabolites (primarily hydroxylated metabolites). Biliary/fecal: 20-40%.
Renal (approximately 70% as unchanged drug and metabolites), biliary/fecal (approximately 25-30%)
Category C
Category C
Antiarrhythmic Agent
Antiarrhythmic Agent